Anthem Biosciences Limited — Updates, 13-08-2025: Press Release

Anthem Biosciences reported a robust start to FY26. Consolidated revenue from operations rose 59.5% YoY to ₹540.2 Cr. Profit after tax (PAT) soared 64.8% YoY to ₹135.8 Cr, with PAT margins at 24%. The CRDMO business significantly drove this growth, with revenues increasing 70.5% YoY to ₹452.7 Cr, indicating a strong ramp-up. Specialty Ingredients added ₹87.5 Cr. EBITDA margins stood at 38%. The company ended the quarter with a strong net cash position of ₹784.8 Cr.